In the global pharmaceutical landscape, a product is only as reliable as its molecular foundation. As regulatory bodies like the FDA and EMA tighten scrutiny on impurity profiling, the transition from "lab-scale success" to "market-ready compliance" ...
Markdown supported · ⌘↵ to post
No responses yet.